{ "instance": { "rmti-20200930.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 338, "dts": { "calculationLink": { "local": [ "rmti-20200930_cal.xml" ] }, "definitionLink": { "local": [ "rmti-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "rmti-20200930.htm" ] }, "labelLink": { "local": [ "rmti-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "rmti-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "rmti-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 488, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 45, "keyStandard": 336, "memberCustom": 39, "memberStandard": 27, "nsprefix": "rmti", "nsuri": "http://rockwellmed.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://rockwellmed.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements", "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements", "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - Revenue Recognition", "role": "http://rockwellmed.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - Investments - Available-for-Sale", "role": "http://rockwellmed.com/role/InvestmentsAvailableforSale", "shortName": "Investments - Available-for-Sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117106 - Disclosure - Inventory", "role": "http://rockwellmed.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120107 - Disclosure - Property And Equipment", "role": "http://rockwellmed.com/role/PropertyAndEquipment", "shortName": "Property And Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123108 - Disclosure - Accrued Liabilities", "role": "http://rockwellmed.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "rmti:ContractWithCustomerDeferredRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126109 - Disclosure - Deferred Revenue", "role": "http://rockwellmed.com/role/DeferredRevenue", "shortName": "Deferred Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "rmti:ContractWithCustomerDeferredRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128110 - Disclosure - Stockholders\u2019 Equity", "role": "http://rockwellmed.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130111 - Disclosure - Stock-Based Compensation", "role": "http://rockwellmed.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140112 - Disclosure - Related Party Transactions", "role": "http://rockwellmed.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142113 - Disclosure - Leases", "role": "http://rockwellmed.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147114 - Disclosure - Commitments and Contingencies", "role": "http://rockwellmed.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149115 - Disclosure - Loans and Security Agreement", "role": "http://rockwellmed.com/role/LoansandSecurityAgreement", "shortName": "Loans and Security Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2205201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)", "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies", "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)", "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables", "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Revenue Recognition (Tables)", "role": "http://rockwellmed.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Investments - Available-for-Sale (Tables)", "role": "http://rockwellmed.com/role/InvestmentsAvailableforSaleTables", "shortName": "Investments - Available-for-Sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Inventory (Tables)", "role": "http://rockwellmed.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321305 - Disclosure - Property And Equipment (Tables)", "role": "http://rockwellmed.com/role/PropertyAndEquipmentTables", "shortName": "Property And Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324306 - Disclosure - Accrued Liabilities (Tables)", "role": "http://rockwellmed.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://rockwellmed.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343308 - Disclosure - Leases (Tables)", "role": "http://rockwellmed.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350309 - Disclosure - Loans and Security Agreement (Tables)", "role": "http://rockwellmed.com/role/LoansandSecurityAgreementTables", "shortName": "Loans and Security Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Liquidity and Capital Resources (Details)", "role": "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails", "shortName": "Liquidity and Capital Resources (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-5", "lang": "en-US", "name": "rmti:WorkingCapitalNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details)", "role": "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails", "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "rmti:NumberOfDistributionAndLicenseAgreements", "reportCount": 1, "unique": true, "unitRef": "agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Revenue Recognition - Nature of Goods and Services (Details)", "role": "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails", "shortName": "Revenue Recognition - Nature of Goods and Services (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "rmti:NumberOfDistributionAndLicenseAgreements", "reportCount": 1, "unique": true, "unitRef": "agreement", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "role": "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i261c70dbb8d0491582918b9a45338ea9_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Revenue Recognition - Contract Balances (Details)", "role": "http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails", "shortName": "Revenue Recognition - Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:ContractWithCustomerAssetCreditLossExpense", "us-gaap:ContractWithCustomerAssetCreditLossExpense", "us-gaap:ContractWithCustomerAssetCreditLossExpense", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Revenue Recognition - Narrative (Details)", "role": "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails", "shortName": "Revenue Recognition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ContractWithCustomerAssetCreditLossExpense", "us-gaap:ContractWithCustomerAssetCreditLossExpense", "us-gaap:ContractWithCustomerAssetCreditLossExpense", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Investments - Available-for-Sale (Details)", "role": "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails", "shortName": "Investments - Available-for-Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Inventory (Details)", "role": "http://rockwellmed.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422409 - Disclosure - Property And Equipment (Details)", "role": "http://rockwellmed.com/role/PropertyAndEquipmentDetails", "shortName": "Property And Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i8b67c739cf8a4c7d8e0b8d14d0465e2e_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425410 - Disclosure - Accrued Liabilities (Details)", "role": "http://rockwellmed.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "rmti:ResearchAndDevelopmentRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427411 - Disclosure - Deferred Revenue (Details)", "role": "http://rockwellmed.com/role/DeferredRevenueDetails", "shortName": "Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i0cbda60e593d4229ac91d5bd7546f437_D20141001-20141031", "decimals": "-6", "lang": "en-US", "name": "rmti:RevenueRecognitionReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429412 - Disclosure - Stockholders\u2019 Equity (Details)", "role": "http://rockwellmed.com/role/StockholdersEquityDetails", "shortName": "Stockholders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "if5ce09a06f0c415393231c1a653fdbc8_D20200101-20200930", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432413 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ib64866686f294a7d9853a8b1810ff7d0_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ieb4dad30bf674f2b81a41e72d5349c55_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433414 - Disclosure - Stock-Based Compensation - Restricted Stock Awards (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "shortName": "Stock-Based Compensation - Restricted Stock Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ieb4dad30bf674f2b81a41e72d5349c55_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434415 - Disclosure - Stock-Based Compensation - Service Based Restricted Stock Units (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "shortName": "Stock-Based Compensation - Service Based Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i56e6576c7ebc4aa2b6e3a0509618dfe5_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435416 - Disclosure - Stock-Based Compensation - Performance Based Restricted Stock Units (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "shortName": "Stock-Based Compensation - Performance Based Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i909683c4233b4a22804c27ebf1e6c92b_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436417 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "shortName": "Stock-Based Compensation - Service Based Stock Options - Fair value assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930", "decimals": "0", "first": true, "lang": "en-US", "name": "rmti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437418 - Disclosure - Stock-Based Compensation - Service Based Stock Options (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "shortName": "Stock-Based Compensation - Service Based Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i26f20cf571ac43b2a4f8b28db21b91ba_D20190101-20190930", "decimals": "0", "first": true, "lang": "en-US", "name": "rmti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438419 - Disclosure - Stock-Based Compensation - Service Based Stock Options - Others (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails", "shortName": "Stock-Based Compensation - Service Based Stock Options - Others (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i3f6c123aff3f44adb997e2b312feda1d_D20200101-20200930", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439420 - Disclosure - Stock-Based Compensation - Performance Based Stock Options (Details)", "role": "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "shortName": "Stock-Based Compensation - Performance Based Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i72f1121abfa849c8b1387a55992b3591_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007", "decimals": "INF", "first": true, "lang": "en-US", "name": "rmti:NumberOfAdditionalAgreements", "reportCount": 1, "unique": true, "unitRef": "agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - Related Party Transactions (Details)", "role": "http://rockwellmed.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i2e0da5d2865549e38aec2425e6c14b44_D20181007-20181007", "decimals": "INF", "first": true, "lang": "en-US", "name": "rmti:NumberOfAdditionalAgreements", "reportCount": 1, "unique": true, "unitRef": "agreement", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444422 - Disclosure - Leases - Narrative (Details)", "role": "http://rockwellmed.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i1a68746f2fdd4216add87ba69b052f3f_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445423 - Disclosure - Leases - Summary of Operating Leases (Details)", "role": "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails", "shortName": "Leases - Summary of Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - Leases - Future Minimum Rental Payments Under Operating Leases (Details)", "role": "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails", "shortName": "Leases - Future Minimum Rental Payments Under Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ibfa2ec5c25ac44e496b725edbf06211d_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448425 - Disclosure - Commitments and Contingencies (Details)", "role": "http://rockwellmed.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i595c11eb52be4aef8a1d93eb8a1ebb0c_D20200201-20200229", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i988157eb43c948b0b48c71a792211e1c_D20200316-20200316", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451426 - Disclosure - Loans and Security Agreement - Narrative (Details)", "role": "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "shortName": "Loans and Security Agreement - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i918e1ec310cd4501850ee5a1d190849e_I20200316", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ia2342dabfb994ca9b8cabed424b37ce7_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452427 - Disclosure - Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)", "role": "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails", "shortName": "Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ia2342dabfb994ca9b8cabed424b37ce7_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i32f5bee8a4224cc9bb993e924ffa5275_I20181231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "i592a526e425b4c9a941c2edad05ae90c_D20190101-20190331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "iad39fc18340148d88260925cf2c71125_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Description of Business", "role": "http://rockwellmed.com/role/DescriptionofBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "rmti:LiquidityAndFinancialConditionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Liquidity and Capital Resources", "role": "http://rockwellmed.com/role/LiquidityandCapitalResources", "shortName": "Liquidity and Capital Resources", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200930.htm", "contextRef": "ie545dc4f03404f20a2faa7953cd18f92_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "rmti:LiquidityAndFinancialConditionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 67, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "verboseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]", "terseLabel": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]", "terseLabel": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r306", "r307" ], "lang": { "en-US": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]", "terseLabel": "Former Address" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://rockwellmed.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "rmti_AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Warrant Modification Expense", "label": "Adjustments to Additional Paid in Capital, Warrant Modification Expense", "terseLabel": "Warrant Modification Expense" } } }, "localname": "AdjustmentstoAdditionalPaidinCapitalWarrantModificationExpense", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "rmti_AssetAcquisitionMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of milestone payments related to asset acquisition.", "label": "Asset Acquisition Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "AssetAcquisitionMilestonePayments", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rmti_AtthemarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At-The-market Offering [Member]", "label": "At-the-market Offering [Member]", "terseLabel": "At-the-market offering" } } }, "localname": "AtthemarketOfferingMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "rmti_AveragePaymentTermOfCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the average payment term of customers.", "label": "Average Payment Term of Customers", "terseLabel": "Customers average payment term" } } }, "localname": "AveragePaymentTermOfCustomers", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" ], "xbrltype": "durationItemType" }, "rmti_AveragePaymentTermOfDistributors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the average payment term of distributors.", "label": "Average Payment Term of Distributors", "terseLabel": "Distributors average payment term" } } }, "localname": "AveragePaymentTermOfDistributors", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" ], "xbrltype": "durationItemType" }, "rmti_BaxterHealthcareOrganizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Baxter Healthcare Organization [Member]", "label": "Baxter Healthcare Organization [Member]", "terseLabel": "Baxter Healthcare Organization" } } }, "localname": "BaxterHealthcareOrganizationMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails", "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_CertainEmployeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This represents information pertaining to certain employees.", "label": "Certain Employees [Member]", "terseLabel": "Employee stock options" } } }, "localname": "CertainEmployeesMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "domainItemType" }, "rmti_ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Chief Executive Officer, Chief Financial Officer, And Director", "label": "Chief Executive Officer, Chief Financial Officer, And Director [Member]", "terseLabel": "Chief executive officer, chief financial officer, and director" } } }, "localname": "ChiefExecutiveOfficerChiefFinancialOfficerAndDirectorMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "domainItemType" }, "rmti_ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded", "label": "Class Of Warrant Or Right, Calculation For Number Of Securities Called By Warrants Or Right, Numerator, Percentage Of Principal Amount Of Debt Instrument Funded", "terseLabel": "Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded" } } }, "localname": "ClassOfWarrantOrRightCalculationForNumberOfSecuritiesCalledByWarrantsOrRightNumeratorPercentageOfPrincipalAmountOfDebtInstrumentFunded", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days", "label": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Execution Of Agreement, Trading Days", "terseLabel": "Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days" } } }, "localname": "ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingExecutionOfAgreementTradingDays", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "integerItemType" }, "rmti_ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days", "label": "Class Of Warrant Or Right, Exercise Price Calculation, Period Immediately Preceding Relevant Funding, Trading Days", "terseLabel": "Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days" } } }, "localname": "ClassOfWarrantOrRightExercisePriceCalculationPeriodImmediatelyPrecedingRelevantFundingTradingDays", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "integerItemType" }, "rmti_ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Holder's Option Upon Issuance, Maximum Ownership Percentage Upon Exercise", "label": "Class Of Warrant Or Right, Holder's Option Upon Issuance, Maximum Ownership Percentage Upon Exercise", "terseLabel": "Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants, at holder's option upon issuance" } } }, "localname": "ClassOfWarrantOrRightHoldersOptionUponIssuanceMaximumOwnershipPercentageUponExercise", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "rmti_ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Maximum Ownership Percentage Upon Exercise", "label": "Class Of Warrant Or Right, Maximum Ownership Percentage Upon Exercise", "terseLabel": "Maximum percentage of outstanding common stock able to be owned immediately after exercise of warrants" } } }, "localname": "ClassOfWarrantOrRightMaximumOwnershipPercentageUponExercise", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "rmti_ConcentrateProductLicenseFeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentrate Product License Fee [Member]", "label": "Concentrate Product License Fee [Member]", "terseLabel": "Concentrate product license fee" } } }, "localname": "ConcentrateProductLicenseFeeMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_ConcentrateProductSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentrate Product Sales [Member]", "label": "Concentrate Product Sales [Member]", "terseLabel": "Concentrate product sales" } } }, "localname": "ConcentrateProductSalesMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_ConcentrateProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentrate Products [Member]", "label": "Concentrate Products [Member]", "terseLabel": "Concentrate Products" } } }, "localname": "ConcentrateProductsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_ContractWithCustomerDeferredRevenueTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with Customer Deferred Revenue [Text Block]", "label": "Contract with Customer Deferred Revenue [Text Block]", "terseLabel": "Deferred Revenue" } } }, "localname": "ContractWithCustomerDeferredRevenueTextBlock", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenue" ], "xbrltype": "textBlockItemType" }, "rmti_CurrentAndNonCurrentInventory": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of current and non-current inventory.", "label": "Current And Non Current Inventory", "totalLabel": "Total" } } }, "localname": "CurrentAndNonCurrentInventory", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "rmti_DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage", "label": "Debt Instrument, Option To Add Interest Rate Amount To Outstanding Principal Balance In Lieu Of Payment, Percentage", "terseLabel": "Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage" } } }, "localname": "DebtInstrumentOptionToAddInterestRateAmountToOutstandingPrincipalBalanceInLieuOfPaymentPercentage", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "rmti_DebtInstrumentPeriodOfInterestOnlyPayments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Period Of Interest-Only Payments", "label": "Debt Instrument, Period Of Interest-Only Payments", "terseLabel": "Period for which company is entitled to make interest-only payments" } } }, "localname": "DebtInstrumentPeriodOfInterestOnlyPayments", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "durationItemType" }, "rmti_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Current", "label": "Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Current", "terseLabel": "Accrued Interest Income" } } }, "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" ], "xbrltype": "monetaryItemType" }, "rmti_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures", "label": "Deferred Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Reduction Due To Forfeitures", "terseLabel": "Estimated expense reduction in stock compensation expense related to forfeited stock awards" } } }, "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseReductionDueToForfeitures", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "monetaryItemType" }, "rmti_DeferredRevenueBenefitPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Revenue Benefit Percentage", "label": "Deferred Revenue Benefit Percentage", "terseLabel": "Refund eligible for, percent of upfront fee" } } }, "localname": "DeferredRevenueBenefitPercentage", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "percentItemType" }, "rmti_DrugLicenseFeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Drug License Fee [Member]", "label": "Drug License Fee [Member]", "terseLabel": "Drug license fee" } } }, "localname": "DrugLicenseFeeMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_DrugProductSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Drug Product Sales [Member]", "label": "Drug Product Sales [Member]", "terseLabel": "Drug product sales" } } }, "localname": "DrugProductSalesMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_DrugRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Drug Revenue [Member]", "label": "Drug Revenue [Member]", "terseLabel": "Drug products" } } }, "localname": "DrugRevenueMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_ExecutiveVicePresidentAndChiefScientificOfficerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to Executive Vice President and Chief Scientific Officer.", "label": "Executive Vice President And Chief Scientific Officer [Member]", "terseLabel": "Executive vice president and chief scientific officer" } } }, "localname": "ExecutiveVicePresidentAndChiefScientificOfficerMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rmti_IncreaseDecreaseInOperatingLeaseLiabilites": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities that result from activities that generate operating income.", "label": "Increase Decrease in Operating Lease Liabilites", "terseLabel": "Decrease in Lease Liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilites", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rmti_InstallmentPaymentToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with installment payment to related parties.", "label": "Installment paid", "terseLabel": "Installment paid" } } }, "localname": "InstallmentPaymentToRelatedParties", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rmti_JeilPharmaAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Jeil Pharma Agreements", "label": "Jeil Pharma Agreements [Member]", "terseLabel": "Jeil Pharma Agreements" } } }, "localname": "JeilPharmaAgreementsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_LeaseFacilityOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Lease facility one.", "label": "Lease Facility One [Member]", "terseLabel": "Lease facility one" } } }, "localname": "LeaseFacilityOneMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_LeaseFacilityTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Lease facility two.", "label": "Lease Facility Two [Member]", "terseLabel": "Lease facility two" } } }, "localname": "LeaseFacilityTwoMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_LiquidityAndFinancialConditionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Liquidity and Capital Resources", "terseLabel": "Liquidity and Capital Resources" } } }, "localname": "LiquidityAndFinancialConditionAbstract", "nsuri": "http://rockwellmed.com/20200930", "xbrltype": "stringItemType" }, "rmti_LiquidityAndFinancialConditionTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of liquidity position and financial conditions.", "label": "Liquidity And Financial Condition [Text Block]", "terseLabel": "Liquidity and Capital Resources" } } }, "localname": "LiquidityAndFinancialConditionTextBlock", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LiquidityandCapitalResources" ], "xbrltype": "textBlockItemType" }, "rmti_MasterServicesAndIpAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Master services and Ip agreements.", "label": "Master Services And Ip Agreement [Member]", "terseLabel": "Master services and IP agreements" } } }, "localname": "MasterServicesAndIpAgreementMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rmti_NumberOfAdditionalAgreements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of additional agreements.", "label": "Number of additional agreements", "terseLabel": "Number of additional agreements" } } }, "localname": "NumberOfAdditionalAgreements", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "rmti_NumberOfDistributionAndLicenseAgreements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of distribution and license agreements.", "label": "Number of Distribution and License Agreements", "terseLabel": "Number of distribution and license agreements" } } }, "localname": "NumberOfDistributionAndLicenseAgreements", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNatureofGoodsandServicesDetails" ], "xbrltype": "integerItemType" }, "rmti_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease Right Of Use Asset Amortization", "label": "Operating Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of Right of Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rmti_PartialRefund": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Partial Refund", "label": "Partial Refund", "terseLabel": "Partial refund" } } }, "localname": "PartialRefund", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "rmti_PaymentsOfStockIssuanceCostsAndCommissionsFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments Of Stock Issuance Costs And Commissions Fees", "label": "Payments Of Stock Issuance Costs And Commissions Fees", "terseLabel": "Commissions and offering fees paid" } } }, "localname": "PaymentsOfStockIssuanceCostsAndCommissionsFees", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "rmti_PaymentsToAcquireAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount paid to acquire assets.", "label": "Payments to Acquire Assets", "terseLabel": "Payments to acquire assets" } } }, "localname": "PaymentsToAcquireAssets", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rmti_PerformanceBasedAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to performance based awards.", "label": "Performance Based Awards [Member]", "terseLabel": "Performance based awards" } } }, "localname": "PerformanceBasedAwardsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "rmti_PerformanceBasedRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "na", "label": "Performance Based Restricted Stock Awards [Member]", "terseLabel": "Restricted stock awards - performance based" } } }, "localname": "PerformanceBasedRestrictedStockAwardsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" ], "xbrltype": "domainItemType" }, "rmti_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Based Restricted Stock Units [Member]", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Restricted stock units - performance based awards" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "rmti_PerformanceBasedStockOptionAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "na", "label": "Performance Based Stock Option Awards [Member]", "terseLabel": "Stock option awards - performance based awards" } } }, "localname": "PerformanceBasedStockOptionAwardsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "rmti_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre-Funded Warrants", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "rmti_PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "President, Chief Executive Officer, And Chief Financial Officer", "label": "President, Chief Executive Officer, And Chief Financial Officer [Member]", "terseLabel": "President, chief executive officer, and chief financial officer" } } }, "localname": "PresidentChiefExecutiveOfficerAndChiefFinancialOfficerMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "domainItemType" }, "rmti_PresidentandChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "President and Chief Executive Officer [Member]", "label": "President and Chief Executive Officer [Member]", "terseLabel": "President and chief executive officer" } } }, "localname": "PresidentandChiefExecutiveOfficerMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "domainItemType" }, "rmti_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs", "label": "Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs", "terseLabel": "Proceeds from issuance of common shares, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "rmti_PublicOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Public Offering [Member]", "label": "Public Offering [Member]", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "rmti_RegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Registered Direct Offering", "label": "Registered Direct Offering [Member]", "terseLabel": "Registered Direct Offering" } } }, "localname": "RegisteredDirectOfferingMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "rmti_RelatedPartyNumberOfInstallmentPayments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related Party Number Of Installment Payments", "label": "Related Party Number Of Installment Payments", "terseLabel": "Number of quarterly installment payments" } } }, "localname": "RelatedPartyNumberOfInstallmentPayments", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "rmti_RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Related Party Transactions, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees", "label": "Related Party Transactions, Accrued Reimbursement of IP Expenses And Sublicense Royalty Fees", "terseLabel": "Related party transactions, accrued reimbursement of IP expenses and sublicense royalty fees" } } }, "localname": "RelatedPartyTransactionsAccruedReimbursementOfIPExpensesAndSublicenseRoyaltyFees", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rmti_RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of related party transactions accrued reimbursement of legal expenses.", "label": "Related Party Transactions Accrued Reimbursement of Legal Expenses", "terseLabel": "Related party transactions, accrued reimbursement of legal expenses" } } }, "localname": "RelatedPartyTransactionsAccruedReimbursementOfLegalExpenses", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rmti_RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Repurchase of common shares to pay employee withholding taxes.", "label": "Repurchase Of Common Shares To Pay Employee Withholding Taxes", "negatedLabel": "Repurchase of Common Stock to Pay Employee Withholding Taxes" } } }, "localname": "RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rmti_ResearchAndDevelopmentRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Research and Development Related Liabilities, Current", "terseLabel": "Accrued Research\u00a0& Development Expense" } } }, "localname": "ResearchAndDevelopmentRelatedLiabilitiesCurrent", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rmti_RevenueRecognitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Recognition [Line Items]", "label": "Revenue Recognition [Line Items]", "terseLabel": "Revenue Recognition [Line Items]" } } }, "localname": "RevenueRecognitionLineItems", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "rmti_RevenueRecognitionReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of consideration received during the period for the milestone.", "label": "Revenue Recognition Received", "terseLabel": "Upfront payment" } } }, "localname": "RevenueRecognitionReceived", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "rmti_RevenueRecognitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Recognition [Table]", "label": "Revenue Recognition [Table]", "terseLabel": "Revenue Recognition [Table]" } } }, "localname": "RevenueRecognitionTable", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "rmti_SaleOfEquityAmountPayableForServicesRelatedToOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sale Of Equity, Amount Payable For Services Related To Offering", "label": "Sale Of Equity, Amount Payable For Services Related To Offering", "terseLabel": "Amount payable to financial advisory firm for services related to offering" } } }, "localname": "SaleOfEquityAmountPayableForServicesRelatedToOffering", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "rmti_SaleOfEquityPlacementAgentFeeClearingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sale Of Equity, Placement Agent Fee, Clearing Fees", "label": "Sale Of Equity, Placement Agent Fee, Clearing Fees", "terseLabel": "Placement agent fee, clearing fees" } } }, "localname": "SaleOfEquityPlacementAgentFeeClearingFees", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "rmti_SaleOfEquityPlacementAgentFeeNonAccountableExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sale Of Equity, Placement Agent Fee, Non-Accountable Expenses", "label": "Sale Of Equity, Placement Agent Fee, Non-Accountable Expenses", "terseLabel": "Placement agent fee, non-accountable expenses" } } }, "localname": "SaleOfEquityPlacementAgentFeeNonAccountableExpenses", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued From Exercise Of Warrants During Remainder Term Of Such Warrants", "label": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued From Exercise Of Warrants During Remainder Term Of Such Warrants", "terseLabel": "Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of any warrants issued in the offering from the exercise of warrants during the remainder term of such warrants" } } }, "localname": "SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedFromExerciseOfWarrantsDuringRemainderTermOfSuchWarrants", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued To Investors", "label": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds From Cash Exercise Of Warrants Issued To Investors", "terseLabel": "Placement agent, cash fee, percentage of aggregate gross proceeds from cash exercise of warrants issued to investors" } } }, "localname": "SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsFromCashExerciseOfWarrantsIssuedToInvestors", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "rmti_SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds Raised In Offering", "label": "Sale Of Equity, Placement Agent Fee, Percentage Of Gross Proceeds Raised In Offering", "terseLabel": "Placement agent, cash fee, percentage of aggregate gross proceeds raised in Offering" } } }, "localname": "SaleOfEquityPlacementAgentFeePercentageOfGrossProceedsRaisedInOffering", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "rmti_SaleofStockRemainingSalesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sale of Stock, Remaining Sales Amount", "label": "Sale of Stock, Remaining Sales Amount", "terseLabel": "Remaining amount available for sale" } } }, "localname": "SaleofStockRemainingSalesAmount", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "rmti_SalesAgreementThresholdSaleOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of threshold offering or sale of shares under the sales agreement.", "label": "Sales Agreement, Threshold Sale Of Shares", "terseLabel": "Sales agreement, threshold sale of shares" } } }, "localname": "SalesAgreementThresholdSaleOfShares", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "rmti_ServiceBasedAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to service based awards.", "label": "Service Based Awards [Member]", "terseLabel": "Service based awards" } } }, "localname": "ServiceBasedAwardsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "rmti_ServiceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "na", "label": "Service Based Restricted Stock Units [Member]", "terseLabel": "Restricted stock units - service based awards", "verboseLabel": "Restricted stock units - service based awards" } } }, "localname": "ServiceBasedRestrictedStockUnitsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "rmti_ServiceBasedStockOptionAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "na", "label": "Service Based Stock Option Awards [Member]", "terseLabel": "Stock option awards - service based awards" } } }, "localname": "ServiceBasedStockOptionAwardsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails", "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "rmti_SettlementAgreementWithAllPartiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represent information relating to settlement agreement with all parties to the class action.", "label": "Settlement Agreement With All Parties [Member]", "terseLabel": "Settlement agreement with all parties" } } }, "localname": "SettlementAgreementWithAllPartiesMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NA", "label": "Aggregate intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Intrinsic Value", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Intrinsic Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "rmti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NA", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "rmti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term 2", "terseLabel": "Granted, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "durationItemType" }, "rmti_SunPharmaAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sun Pharma Agreements [Member]", "label": "Sun Pharma Agreements [Member]", "terseLabel": "Sun Pharma Agreements" } } }, "localname": "SunPharmaAgreementsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_SupplyAgreementPercentageOfRawMaterialsPaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supply Agreement, Percentage Of Raw Materials Paid", "label": "Supply Agreement, Percentage Of Raw Materials Paid", "terseLabel": "Percentage of raw materials paid" } } }, "localname": "SupplyAgreementPercentageOfRawMaterialsPaid", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "rmti_SupplyAgreementPercentageOfRawMaterialsToBePaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supply Agreement, Percentage Of Raw Materials To Be Paid", "label": "Supply Agreement, Percentage Of Raw Materials To Be Paid", "terseLabel": "Percentage of raw materials to be paid" } } }, "localname": "SupplyAgreementPercentageOfRawMaterialsToBePaid", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "rmti_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan [Member]", "label": "Term Loan [Member]", "terseLabel": "Term loan" } } }, "localname": "TermLoanMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "domainItemType" }, "rmti_TermLoanTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan, Tranche One [Member]", "label": "Term Loan, Tranche One [Member]", "terseLabel": "Term loan, first tranche" } } }, "localname": "TermLoanTrancheOneMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_TermLoanTrancheThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan, Tranche Three [Member]", "label": "Term Loan, Tranche Three [Member]", "terseLabel": "Term loan, third tranche" } } }, "localname": "TermLoanTrancheThreeMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_TermLoanTrancheTwoAndTrancheThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan, Tranche Two And Tranche Three [Member]", "label": "Term Loan, Tranche Two And Tranche Three [Member]", "terseLabel": "Term loan, second and third tranches" } } }, "localname": "TermLoanTrancheTwoAndTrancheThreeMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_TermLoanTrancheTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan, Tranche Two [Member]", "label": "Term Loan, Tranche Two [Member]", "terseLabel": "Term loan, second tranche" } } }, "localname": "TermLoanTrancheTwoMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "rmti_TrifericAPIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Triferic API [Member]", "label": "Triferic API [Member]", "terseLabel": "Triferic API" } } }, "localname": "TrifericAPIMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "domainItemType" }, "rmti_TrifericDialysateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Triferic Dialysate [Member]", "label": "Triferic Dialysate [Member]", "terseLabel": "Triferic Dialysate" } } }, "localname": "TrifericDialysateMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "domainItemType" }, "rmti_TrifericInventoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Triferic Inventory [Member]", "label": "Triferic Inventory [Member]", "terseLabel": "Triferic Inventory" } } }, "localname": "TrifericInventoryMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "domainItemType" }, "rmti_WanbangBiopharmaceuticalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co., Ltd. (\u201cWanbang\u201d) for the rights to commercialize the Triferic and Calcitriol drugs.", "label": "Wanbang Biopharmaceutical [Member]", "terseLabel": "Wanbang Biopharmaceutical" } } }, "localname": "WanbangBiopharmaceuticalMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "rmti_WarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Warrants", "label": "Warrants [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantsMember", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "rmti_WorkingCapitalNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the monetary amount of working capital, as of the indicated date.", "label": "Working Capital Net", "terseLabel": "Working capital net" } } }, "localname": "WorkingCapitalNet", "nsuri": "http://rockwellmed.com/20200930", "presentation": [ "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Chief financial officer" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r54", "r102" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails", "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r127", "r199", "r203", "r297", "r298" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails", "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails", "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r128", "r199", "r204", "r299", "r300", "r301" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails", "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r156", "r278" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r129", "r272" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "domainItemType" }, "stpr_MI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MICHIGAN", "terseLabel": "Wixom, Michigan" } } }, "localname": "MI", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_NJ": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW JERSEY", "terseLabel": "Hackensack, New Jersey" } } }, "localname": "NJ", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_SC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SOUTH CAROLINA", "terseLabel": "Greer, South Carolina" } } }, "localname": "SC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TEXAS", "terseLabel": "Grapevine, Texas" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r18", "r130", "r131", "r200" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts Receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://rockwellmed.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued Liabilities", "totalLabel": "Total Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilitiesDetails", "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Costs, Current", "terseLabel": "Accrued Marketing Expenses" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r8", "r39" ], "calculation": { "http://rockwellmed.com/role/AccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued Legal Expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r151" ], "calculation": { "http://rockwellmed.com/role/PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r59", "r60", "r61" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r58", "r61", "r62", "r240" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "ADDITIONAL PAID-IN CAPITAL" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "verboseLabel": "Stock-based Compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r170", "r181", "r188" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of Warrants related to Debt Financing" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r208", "r231", "r236" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock based compensation expenses", "verboseLabel": "Total share based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails", "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r91", "r250" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of Debt Financing Costs and Accretion of Debt Discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Securities excluded from diluted loss per share calculation (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Earnings per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "verboseLabel": "Facility sqft." } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails", "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r126", "r279", "r289" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r53" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r136" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r134", "r141" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "netLabel": "Investments available-for-sale", "terseLabel": "Investments Available-for-Sale", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails", "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r209", "r233" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails", "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r32", "r93" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and Cash Equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r87", "r93", "r98" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents at End of Period", "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r87", "r245" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Increase (Decrease) in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r107", "r189", "r207" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares of common stock each warrant is exercisable for (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r105" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of shares of common stock for which warrant is exercisable (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r155", "r284", "r294" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (See Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r154", "r165" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (up to) (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "COMMON STOCK" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r181" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "End balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common shares, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r17" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Amount allocated to common stock", "verboseLabel": "Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,573,165 and 65,378,890 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Contract balances" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetCreditLossExpense": { "auth_ref": [ "r140", "r194", "r198" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)", "terseLabel": "Impairment losses" } } }, "localname": "ContractWithCustomerAssetCreditLossExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r191", "r193", "r200" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r191", "r192", "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails", "http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r191", "r192", "r200" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred License Revenue - Current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r191", "r192", "r200" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred License Revenue - Long-Term" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Recognized deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiability": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.", "label": "Contract with Customer, Refund Liability", "verboseLabel": "Reserve for returns" } } }, "localname": "ContractWithCustomerRefundLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r202" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Customer Deposits" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r71" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Loans and Security Agreement" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r280", "r281", "r288" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate, additional percentage added to base percentage" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r15", "r171", "r281", "r288" ], "calculation": { "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Principal Payments" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r249", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r41", "r249" ], "lang": { "en-US": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Initial interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r41", "r174", "r249" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "verboseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate, base percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r104", "r182", "r185", "r186", "r187", "r248", "r249", "r251", "r287" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r248", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Additional debt discount recognized" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r172", "r250" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Unamortized issuance costs and unaccreted discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "auth_ref": [ "r141" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Amortized Cost, Current", "terseLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InvestmentsAvailableforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r137" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)", "terseLabel": "Realized Gain on Investments" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Investments available for sale" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InvestmentsAvailableforSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue Arrangement, by Type [Table]", "terseLabel": "Deferred Revenue Arrangement, by Type [Table]" } } }, "localname": "DeferredRevenueArrangementByTypeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Revenue Arrangement [Line Items]", "terseLabel": "Deferred Revenue Arrangement [Line Items]" } } }, "localname": "DeferredRevenueArrangementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/DeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r91", "r149" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r91", "r125" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r36", "r108", "r270" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Other Current Liability - Related Party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r108", "r270", "r283", "r295" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Total amount due" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r99", "r113", "r114", "r115" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://rockwellmed.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued Compensation and Benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, weighted average remaining term (in years)", "verboseLabel": "Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expenses" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r91", "r177" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedTerseLabel": "Warrant Modification Expense", "terseLabel": "Warrant Modification Expense" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r242", "r243", "r244" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r91" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Loss (Gain) on Disposal of Assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r91" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "negatedLabel": "Realized (Gain) on Sale of Investments Available-for-Sale" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r147", "r148" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r70" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase (Decrease) in Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease in Accounts Receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Decrease in Deferred License Revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInsuranceLiabilities": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) in insurance liability balances during the period.", "label": "Increase (Decrease) in Insurance Liabilities", "verboseLabel": "Decrease in Settlement Payable" } } }, "localname": "IncreaseDecreaseInInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date.", "label": "Increase (Decrease) in Insurance Settlements Receivable", "negatedLabel": "Decrease in Insurance Receivable" } } }, "localname": "IncreaseDecreaseInInsuranceSettlementsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "(Increase) Decrease in Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedTotalLabel": "Changes in Assets and Liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in Assets and Liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Increase (Decrease) in Other Liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_IncreaseDecreaseInOperatingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Decrease in Prepaid and Other Assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r68", "r124", "r247", "r250", "r286" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r74", "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r86", "r88", "r94" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash Paid for Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r24", "r145" ], "calculation": { "http://rockwellmed.com/role/InventoryDetails": { "order": 3.0, "parentTag": "rmti_CurrentAndNonCurrentInventory", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished Goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r47" ], "calculation": { "http://rockwellmed.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "terseLabel": "Inventory, gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReservePeriodCharge": { "auth_ref": [ "r49", "r50", "r51", "r143" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.", "label": "Inventory, LIFO Reserve, Period Charge", "terseLabel": "Increase in Inventory Reserves" } } }, "localname": "InventoryLIFOReservePeriodCharge", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r47", "r142" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://rockwellmed.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventory, noncurrent", "verboseLabel": "Inventory, Non-Current" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r26", "r145" ], "calculation": { "http://rockwellmed.com/role/InventoryDetails": { "order": 1.0, "parentTag": "rmti_CurrentAndNonCurrentInventory", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r47", "r110", "r142", "r144" ], "calculation": { "http://rockwellmed.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory, reserve" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r25", "r145" ], "calculation": { "http://rockwellmed.com/role/InventoryDetails": { "order": 2.0, "parentTag": "rmti_CurrentAndNonCurrentInventory", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in Process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r73", "r123" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest Income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.", "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]", "terseLabel": "Investments - Available-for-Sale" } } }, "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InvestmentsAvailableforSale" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r266", "r268" ], "calculation": { "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total rent expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of operating leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future minimum rental payments under operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r267" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r267" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Year ending December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r267" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Year ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r267" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Year ending December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r267" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Year ending December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r267" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Year ending December 31, 2020 (remaining)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r267" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r282", "r292" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r43", "r155", "r164" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Settlement Payable" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement amount" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Settlement Expense", "verboseLabel": "Settlement expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r173", "r281", "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Outstanding balance, net of unamortized issuance costs and unaccreted discount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r109", "r168" ], "calculation": { "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r109", "r168" ], "calculation": { "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r109", "r168" ], "calculation": { "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r109", "r168" ], "calculation": { "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r109", "r168" ], "calculation": { "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r109" ], "calculation": { "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Term Loan, Net of Issuance Costs" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r169" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r155", "r156", "r157", "r159", "r160", "r161", "r163", "r166", "r167" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r155", "r158", "r162" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Amount of penalties sought from supplier" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Term loan" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementScheduleofPrincipalPaymentsonTermLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash Provided By Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash Provided By (Used In) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows From Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r87", "r89", "r92" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Cash Used In Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows From Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r63", "r65", "r69", "r92", "r114", "r285", "r296" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Loss", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Adoption of Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "verboseLabel": "Rest of World" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosure of Noncash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAssumed1": { "auth_ref": [ "r95", "r96", "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of notes assumed in noncash investing or financing activities.", "label": "Notes Assumed", "terseLabel": "Insurance Financing Note Payable" } } }, "localname": "NotesAssumed1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r15", "r281", "r290" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Insurance Financing Note Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Information Technology\u00a0& Office Equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r259", "r268" ], "calculation": { "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r254" ], "calculation": { "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "totalLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r253" ], "calculation": { "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesFutureMinimumRentalPaymentsUnderOperatingLeasesDetails", "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r253" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease Liability - Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r253" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease Liability - Long-Term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r255", "r262" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r252" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of Use Assets, net", "verboseLabel": "Operating lease, right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r265", "r268" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate \u2013 operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r264", "r268" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term \u2013 operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r241" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/DescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r8", "r9", "r39" ], "calculation": { "http://rockwellmed.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Accrued Liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other Non-Current Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r56", "r57", "r59" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments", "verboseLabel": "Unrealized Gain (Loss) on Available-for-Sale Investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r55", "r246" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign Currency Translation Adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r56", "r59", "r138" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax", "terseLabel": "Change in Unrealized Loss on Marketable Securities Available-for-Sale" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherMachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.", "label": "Other Machinery and Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "OtherMachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total Other Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Receivables, which are included in \"Trade and other receivables\"" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over allotment" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r84" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt Issuance Costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "terseLabel": "Closing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r85" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Offering Costs from the Issuance of Common Stock / Public Offering", "terseLabel": "Common share issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r76", "r78", "r133" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Purchase of Investments Available-for-Sale" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r79" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "negatedLabel": "Purchase of Research and Development Licenses (Related Party)" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r80" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "negatedLabel": "Purchase of Equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred shares, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, shares authorized (in shares)", "verboseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred shares, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred shares, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r16" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r30", "r31" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid and Other Current Assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net draw down proceeds" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails", "http://rockwellmed.com/role/LoansandSecurityAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r81" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from the Issuance of Common Stock / Public Offering", "verboseLabel": "Proceeds from the issuance of common shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r82" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from Term Loan" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross proceeds from issuance of common stock and warrants" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r76", "r77", "r133" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Sale of Investments Available-for-Sale" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r81", "r234" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the Exercise of Employee Stock Options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r152" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r150" ], "calculation": { "http://rockwellmed.com/role/PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Gross property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r152", "r293" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://rockwellmed.com/role/PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and Equipment, net", "totalLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of major classes of property and equipment, stated at cost" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r150" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r27" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r83" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Payments on Short Term Note Payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r238", "r302" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and Product Development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r188", "r291" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "ACCUMULATED DEFICIT" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r197", "r199" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Net Revenue", "verboseLabel": "Net Sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r263", "r268" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right of use assets exchanged for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Common shares sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LiquidityandCapitalResourcesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of potentially dilutive securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r208", "r230", "r236" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r208", "r230", "r236" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of total stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r27", "r28", "r29" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule components of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of principal payments on term loan" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LoansandSecurityAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r152" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r101", "r271", "r273", "r274", "r275", "r276" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r209", "r233" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock award" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r212", "r224", "r225" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of stock option assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r44", "r103", "r178", "r179", "r180", "r182", "r183", "r184", "r185", "r186", "r187", "r188" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Selling and Marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of period (in shares)", "periodStartLabel": "Unvested at beginning of period (in shares)", "verboseLabel": "Unvested, number of shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at end of period (in dollars per share)", "periodStartLabel": "Unvested at beginning of period (in dollars per share)", "verboseLabel": "Unvested, weighted average grant-date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "verboseLabel": "Fair value assumptions:" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "verboseLabel": "Stock option awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expirations (in shares)", "terseLabel": "Expirations (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)", "terseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r214", "r233" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares Underlying Options", "verboseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r207", "r211" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationRestrictedStockAwardsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedRestrictedStockUnitsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsOthersDetails", "http://rockwellmed.com/role/StockBasedCompensationSharebasedcompensationexpenseDetails", "http://rockwellmed.com/role/StockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average selling price (in dollars per share)", "verboseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expirations (in dollar per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationPerformanceBasedStockOptionsDetails", "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r228", "r235" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsFairvalueassumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r260", "r268" ], "calculation": { "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease rent expense" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r46", "r181" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r95", "r96", "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Fair Value of Warrants issued related to Debt Financing" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r181", "r188" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of offering costs (in shares)", "verboseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r16", "r17", "r181", "r188" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of / Delivery of common stock underlying Restricted Stock Units Issued, net of taxes withheld (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r181", "r188", "r217" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of employee stock options, net of tax (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockBasedCompensationServiceBasedStockOptionsDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r181", "r188" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r181", "r188" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of Restricted Stock Units Issued, net of taxes withheld" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.", "label": "Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)", "terseLabel": "Exercise of Employee Stock Options, Net of Tax" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r132" ], "calculation": { "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "End balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/StockholdersEquityDetails", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]", "terseLabel": "Product Sales \u2013 Point-in-time" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]", "terseLabel": "License Fee \u2013 Over time" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesNarrativeDetails", "http://rockwellmed.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r116", "r117", "r118", "r119", "r120", "r121", "r122" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r261", "r268" ], "calculation": { "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/LeasesSummaryofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandRecentAccountingPronouncementsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://rockwellmed.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.L)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r303": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r304": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r305": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r306": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r307": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r308": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r309": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" } }, "version": "2.1" }